Dimensional Fund Advisors
MGX icon

Dimensional Fund Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Dimensional Fund Advisors’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$13.6K Hold
12,797
– – ﹤0.01% 3223
2026
Q2 		$15.2K Hold
12,797
– – ﹤0.01% 3216
2026
Q1 		$17.1K Sell
12,797
-986
-7% -$1.53K ﹤0.01% 3210
2025
Q4 		$22.3K Buy
+13,783
New +$29.8K ﹤0.01% 3234

Other funds holding MGX

Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
FAG
Fortitude Advisory Group Gig Harbor, Washington $262M AUM 30.62% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Dimensional Fund Advisors's MGX Position: Q3 2026 in Review

Dimensional Fund Advisors held its Metagenomi Therapeutics (MGX) position steady in Q3 2026 at 12,797 shares worth $13.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3223.

Dimensional Fund Advisors first reported a position in MGX in Q4 2025 and has held it in 4 quarters since. The position peaked at $22.3K in Q4 2025. 8 funds tracked by Wall St. Rank hold MGX as of Q3 2026.

  • Dimensional Fund Advisors held 12,797 shares of Metagenomi Therapeutics worth $13.6K as of Q3 2026.
  • Dimensional Fund Advisors left its Metagenomi Therapeutics share count unchanged in Q3 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #3223 holding.
  • Dimensional Fund Advisors first reported a position in Metagenomi Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Dimensional Fund Advisors's Metagenomi Therapeutics position peaked at $22.3K in Q4 2025.
  • 8 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.